SciELO - Scientific Electronic Library Online

 
vol.76 número3Asociación entre insuficiencia cardíaca derecha y mortalidad hospilataria en exacerbación de la EPOCRuptura cardíaca por trauma contuso de tórax. Un caso inusual índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Neumología y cirugía de tórax

versión impresa ISSN 0028-3746

Neumol. cir. torax vol.76 no.3 México jul./sep. 2017

 

Casos Clínicos

Chronic cough, wheezing and dyspnea: bronchiectasis and aspergillosis

Tos crónica, sibilancia y disnea: bronquiectasia y aspergilosis

Vitorino Modesto dos Santos*    + 

Christiane Aires Teixeira§ 

Viviane Vieira Passini Soares* 

Samuel Abner da Cruz Silva* 

Mayza Lemes Duarte* 

*Catholic University Medical Course

Armed Forces Hospital, Brasília-DF, Brazil

§Preceptor of Pneumology

Abstract

A 76-year-old woman with antecedent of bronchiectasis and productive cough during four months was admitted because of worsening of cough six hours ago. She had been under prolonged broad-spectrum antibiotic therapy without improvement. During admission the chest images and laboratory evaluations established the diagnosis of lung aspergillosis. Chronic pulmonary aspergillosis manifests as cavity, fibrosis, aspergilloma or nodules. The diagnosis depends on typical pulmonary images and microscopy and culture evidence of the fungus or positivity of the specific serologic tests for Aspergillus. It is mandatory to rule out other hypothesis, in special tuberculosis. The role of galactomannan test is also commented.

Key words: Aspergillus; pulmonary aspergillosis; galactomannan

Resumen

Una mujer de 76 años de edad con antecedente de bronquiectasias y tos productiva durante cuatro meses fue admitida debido al empeoramiento de la tos hace seis horas. Había estado bajo terapia antibiótica de largo espectro prolongada sin mejoría. Durante el ingreso, las imágenes torácicas y las evaluaciones de laboratorio establecieron el diagnóstico de aspergilosis pulmonar. La aspergilosis pulmonar crónica se manifiesta como cavidad, fibrosis, aspergiloma o nódulos. El diagnóstico depende de imágenes pulmonares típicas y evidencia del hongo en la microscopia y cultivo, o la positividad de las pruebas serológicas específicas para Aspergillus. Es obligatorio descartar otras hipótesis, la tuberculosis en especial. También se comenta el papel de la prueba de galactomanano.

Palabras clave: Aspergillus; aspergilosis pulmonar; galactomanano

Introduction

Chronic pulmonary aspergillosis (CPA) is an uncommon condition associated with diverse respiratory disorders, and is usually manifested as cavities or fibrosing changes; however, classical aspergilloma or nodular lesions may be observed in some cases.1,2 In developing areas, tuberculosis can precede or coexist with this fungal infection.1,3 The diagnosis is based on typical pulmonary images and microscopy or culture evidence of the fungus or positivity of the specific serologic test for Aspergillus.1-5 Worthy of note is the necessity of excluding diverse alternative causal agents, and pulmonary tuberculosis has been the main differential task in low income regions.1,3 The aim of this report is enhance the suspicion index about aspergillosis and briefly comment the role of galactomannan test, that may have controversial clinical impact in immunosuppressed patients with aspergillosis. The sensitivity and specificity as well as the cut-off level differ from immunocompetent ones.1,4,5

Case report

A 76-year-old woman with clinical history of bronchiectasis and depression came to emergency attention complaining of back pain after an episode of cough six hours ago. She had been with productive cough during four months and used moxifloxacin (10 days), amoxicillin and clavulanate (10 days); followed by moxifloxacin (14 days) without clinical improvement. Therefore, she was admitted for diagnostic investigation and additional treatment with piperacillin and tazobactam (4.5 g t.i.d.) during 14 days. Physical status was regular, BMI: 14.4 kg/m2, and the rest of the exam unremarkable. The chest tomography without contrast showed small scattered nodules with attenuation of soft tissue, the most conspicuous (0.8 x 0.7 cm) on the left posterior basal segment; bilateral ground-glass opacity and tree-in-bud images; and multiple bronchiectasis more evident in both bases (Figure 1). Tuberculosis and aspergillosis were then hypothesized. Routine laboratory determinations were unremarkable, except for neutrophilic leukocytosis, and moderate elevation of urea and of C-reactive protein levels (Table 1). Repeated bacilloscopy and cultures for M. tuberculosis in samples of bronchoalveolar lavages resulted negative; PCR for M. tuberculosis was also negative. Mycological evaluations of bronchoalveolar samples were negative, but ELISA test for Aspergillus antigen (galactomannan) was positive 0.7 (limit: < 0.5 index). The initial galatomannan test was performed during the use of piperacillin and tazobactam; however, the control test was negative with course of itraconazole. The anti-HIV test was negative. CA 125 and CEA were normal; and CA-19.9 was elevated 49.84 (< 34), but the evaluation of pancreatic and hepatobiliary areas ruled out malignancy. She underwent oral itraconazole and became symptomless, being referred to outpatient follow-up at Pneumology service. Furthermore, the study of image done to evaluate the response to the antifungal agents showed significant decrease in the nodes and in the ground glass changes initially observed. This evidence was also considered consistent with the diagnosis of probable aspergillosis.

Figure 1 Chest CT without contrast showing small scattered nodules up to 0.8 x 0.7 cm with attenuation of soft tissue on the left posterior basal segment; bilateral ground-glass opacity and tree-in-bud images; and multiple bronchiectasis that are more evident in both bases. 

Table 1 Laboratory tests of a 76-year-old woman with chronic cough.  

Discussion

Invasive aspergillosis, CPA, allergic bronchopulmonary aspergillosis and aspergilloma are clinical features of fungal infections caused by agents of the genus Aspergillus.1-4 Invasive aspergillosis is often late diagnosed and associated with high mortality rate, and pulmonary foci represent the major primary origin of widespread infections.1,2,5 Since 2002, the incidence of invasive pulmonary aspergillosis has growing, at least partially due to the increased utilization of the galactomannan test for diagnosis.4,5 Clinical diagnosis of aspergillosis is often challenging and depends on complementary tools. In the patient herein described, the diagnosis of CPA was established with some delay because of non-specific manifestations.4,5 here attributed to bronchiectasis sequels. Moreover, the long standing course of cough, dyspnea and wheezing in association with blood eosinophilia might propitiate the mistaken diagnosis of bronchial asthma episodes. Allergic bronchopulmonary aspergillosis can affect asthmatic people causing bronchiectasis. The hypothesis was considered, but Aspergillus was not found in bronchoalveolar lavages, nor was central bronchiectasis in absence of cystic fibrosis found in the present case study. A major concern was Aspergillus-induced asthma, but the episodes were mild, with short duration and moderate eosinophilia, and the patient never utilized corticosteroids for control. Accordingly with the literature about aspergillosis, the eosinophil count, erythrocyte sedimentation rate, and C-reactive protein levels were higher than normal range.1-3 The positive ELISA galactomannan serum test for Aspergillus (0.7) was considered significant. Galactomannan is a heat-stable hetero polysaccharide released during hyphal growth, and ELISA has higher sensitivity and earlier positivity than latex agglutination method. The test has variable sensitivity (29-100%) and both false-negative or false-positive results have been described. These are related to the species of Aspergillus, anti-Aspergillus antibodies, concomitant administration of some antibiotics, and cross-reactivity with Fusarium sp., Alternaria sp., and Mucor sp.4,5 False positivity may occur in patients using piperacillin/tazobactam or amoxicillin/clavulanate (up to six days) or calcium gluconate (up to 48 hrs) before to collections. Microorganisms were not found in bronchoalveolar lavages, and the use of amoxicillin had stopped 14 days before the collection of samples for the exams. The initial collection of sample for the galactomannan test was done during the use of piperacillin and tazobactam; but false-positive tests are lower than 0.5 and the control test after itraconazole was negative. So, the possibility of false-positive test due to the antibiotic use was considered ruled out. The older patient was immunocompetent but had chronic cough due to bronchiectasis. The main initial concerns were about pulmonary tuberculosis or other fungal infection. Microorganisms were not shown by microscopy or culture of bronchoalveolar lavages; but clinical, imaging and laboratory data were consistent with diagnosis of chronic pulmonary aspergillosis that was successfully treated by itraconazole.

Conclusions

Older immunocompetent individuals with chronic cough due to chronic pulmonary disorders are common in developing regions, and unsuspected aspergillosis may occur. The major concern is about the hypothesis of tuberculosis, due to its higher prevalence. Non-specific clinical and imaging manifestations have contributed to diagnostic pitfalls. In this setting, one must take on account the practical usefulness of galactomannan test to confirm diagnosis. The best routine procedure should be concomitantly performing the test in bronchoalveolar aspirate and serum samples; however, this was not done in the woman herein described. Without piperacillin/tazobactam use, the galactomannan test of control was negative after three weeks of the antifungal schedule. It is worth noting that the images of control showed improvement of the pulmonary changes, consistent with diagnosis of probable aspergillosis. Case reports may enhance the suspicion index about less common pulmonary conditions, contributing to establishment of early diagnosis and the early beginning of proper treatment.

References

1. Denning DW, Cadranel J, Beigelman-Aubry C, et al; European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016;47:45-68. doi: 10.1183/13993003.00583-2015. [ Links ]

2. Dos Santos VM, da Trindade MC, de Souza DW, de Menezes AI, Oguma PM, Nascimento AL. A 76-year-old man with a right lung adenocarcinoma and invasive aspergillosis. Mycopathologia 2013;176(1-2):113-118. doi: 10.1007/s11046-013-9651-2. [ Links ]

3. Muthu V, Behera D, Argawal R. Allergic bronchopulmonary aspergillosis or pulmonary tuberculosis: a case of mistaken identity? Lung India 2015;32(5):529-530. doi: 10.4103/0970-2113.164191. [ Links ]

4. Ambasta A, Carson J, Church DL. The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients. Med Mycol 2015;53(6):531-557. doi: 10.1093/mmy/myv026. [ Links ]

5. Sun KS, Tsai CF, Chen SC, Chen YY, Huang WC. Galactomannan testing and the incidence of invasive pulmonary aspergillosis: a 10-Year Nationwide population-based study in Taiwan. PLoS One 2016;11(2):e0149964. doi: 10.1371/journal.pone.0149964. [ Links ]

Recibido: 03 de Noviembre de 2016; Aprobado: 09 de Enero de 2017

Corresponding author: PhD. Vitorino Modesto dos Santos Armed Forces Hospital. Estrada do Contorno do Bosque s/n, Cruzeiro Novo, 70658-900, Brasília-DF, Brazil. Telephone: #55-61 39662103 Fax: #55-61 32331599 E-mail: vitorinomodesto@gmail.com

Disclosure of potential conflicts of interest: The author had full freedom of manuscript preparation and there were no potential conflicts of interest.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License